# Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

> **NCT01951118** · PHASE4 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 121 (actual)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment
- Delirium, Dementia, Amnestic, Cognitive Disorders

## Interventions

- **DRUG:** Donepezil

## Key facts

- **NCT ID:** NCT01951118
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2020-07-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951118, "Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01951118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*